Lenalidomide Teva

Lenalidomide, the active ingredient in Lenalidomide Teva, is a Immunomodulatory agent (IMiD) presented as an oral tablet for systemic use. It is indicated for certain blood cancers and is prescribed for adult patients with specific disease subtypes.

GNH USA supplies Lenalidomide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide Teva is used in hematologic malignancies that respond to immunomodulatory therapy. - Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: enhances response when combined with standard chemotherapy regimens.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: mild to moderate tiredness reported by many patients. - Diarrhea: loose stools, often manageable with supportive care. - Rash: skin erythema or pruritus. - Nausea: occasional upset stomach. - Constipation: reduced bowel movements. - Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophil counts increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary malignancies: rare development of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications. - Pregnancy risk: contraindicated in pregnancy due to teratogenicity; ensure effective contraception. - Thrombosis risk: evaluate need for prophylactic anticoagulation in high‑risk patients. - Renal function: adjust monitoring in patients with impaired kidney function. - Hepatic function: monitor liver enzymes regularly. - Drug hypersensitivity: discontinue if severe allergic reaction occurs. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with lenalidomide‑associated thrombocytopenia.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., cyclosporine, tacrolimus): may enhance immunomodulatory effects. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): modestly increase plasma levels. - Live vaccines: reduced efficacy; avoid concurrent administration.